MedKoo Cat#: 556064 | Name: IXA4
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

IXA4 is a highly selective, non-toxic IRE1/XBP1s activator. IXA4 transiently activates protective IRE1/XBP1s signaling in liver without inducing RIDD or TRAF2/JNK signaling. IXA4 treatment improves systemic glucose metabolism and liver insulin action through IRE1-dependent remodeling of the hepatic transcriptome that reduces glucose production and steatosis. IXA4-stimulated IRE1 activation also enhances pancreatic function. Our findings indicate that systemic, transient activation of IRE1/XBP1s signaling engenders multi-tissue benefits that integrate to mitigate obesity-driven metabolic dysfunction.

Chemical Structure

IXA4
IXA4
CAS#1185329-96-7

Theoretical Analysis

MedKoo Cat#: 556064

Name: IXA4

CAS#: 1185329-96-7

Chemical Formula: C24H28N4O4

Exact Mass: 436.2111

Molecular Weight: 436.51

Elemental Analysis: C, 66.04; H, 6.47; N, 12.84; O, 14.66

Price and Availability

Size Price Availability Quantity
5mg USD 120.00 Ready to ship
10mg USD 190.00 Ready to ship
25mg USD 350.00 Ready to ship
50mg USD 550.00 Ready to ship
100mg USD 950.00 Ready to ship
200mg USD 1,450.00 Ready to ship
500mg USD 2,850.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
IXA4; IXA-4; IXA 4;
IUPAC/Chemical Name
N-(1-(2-(methyl(2-(p-tolyloxy)ethyl)amino)-2-oxoethyl)-1H-pyrazol-4-yl)-3-phenoxypropanamide
InChi Key
ZVSKMVAWWBSNOY-UHFFFAOYSA-N
InChi Code
InChI=1S/C24H28N4O4/c1-19-8-10-22(11-9-19)32-15-13-27(2)24(30)18-28-17-20(16-25-28)26-23(29)12-14-31-21-6-4-3-5-7-21/h3-11,16-17H,12-15,18H2,1-2H3,(H,26,29)
SMILES Code
CC1=CC=C(OCCN(C(CN2N=CC(NC(=O)CCOC3=CC=CC=C3)=C2)=O)C)C=C1
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Biological target:
IXA4 is a highly selective, non-toxic IRE1/XBP1s activator. IXA4 (10 μM; 4 hours) selectively upregulates XBP1s mRNA, relative to genes regulated by ATF6 (e.g., BiP) or PERK (e.g., CHOP), in other cell lines including Huh7 and SHSY5Y cells.
In vitro activity:
IXA4 reduced Aβ levels 50% in conditioned media prepared on CHO7PA2 cells expressing the V717F APP (APPV717F) mutant (Fig. 5B). This study confirmed compound-dependent IRE1/XBP1s activation in these cells by qPCR (Extended Data Fig. 7C). Reference: Nat Chem Biol. 2020 Oct;16(10):1052-1061. https://pubmed.ncbi.nlm.nih.gov/32690944/
In vivo activity:
TBD
Solvent mg/mL mM
Solubility
dmso 93.5 214.20
Ethanol 11.0 25.20
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 436.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Grandjean JMD, Madhavan A, Cech L, Seguinot BO, Paxman RJ, Smith E, Scampavia L, Powers ET, Cooley CB, Plate L, Spicer TP, Kelly JW, Wiseman RL. Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nat Chem Biol. 2020 Oct;16(10):1052-1061. doi: 10.1038/s41589-020-0584-z. Epub 2020 Jul 20. PMID: 32690944; PMCID: PMC7502540.
In vitro protocol:
1. Grandjean JMD, Madhavan A, Cech L, Seguinot BO, Paxman RJ, Smith E, Scampavia L, Powers ET, Cooley CB, Plate L, Spicer TP, Kelly JW, Wiseman RL. Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming. Nat Chem Biol. 2020 Oct;16(10):1052-1061. doi: 10.1038/s41589-020-0584-z. Epub 2020 Jul 20. PMID: 32690944; PMCID: PMC7502540.
In vivo protocol:
TBD
1: Madhavan A, Kok BP, Rius B, Grandjean JMD, Alabi A, Albert V, Sukiasyan A, Powers ET, Galmozzi A, Saez E, Wiseman RL. Pharmacologic IRE1/XBP1s activation promotes systemic adaptive remodeling in obesity. Nat Commun. 2022 Feb 1;13(1):608. doi: 10.1038/s41467-022-28271-2. PMID: 35105890; PMCID: PMC8807832. 2: Grandjean JMD, Wiseman RL. Small molecule strategies to harness the unfolded protein response: where do we go from here? J Biol Chem. 2020 Nov 13;295(46):15692-15711. doi: 10.1074/jbc.REV120.010218. Epub 2020 Sep 4. PMID: 32887796; PMCID: PMC7667976.